# US 10,899,712 B2 · Multi-tyrosine kinase inhibitors derivatives and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,899,712 B2
- Document ID: US10899712B2
- Status: Granted
- Kind: B2
- Application number: 16/517,879
- Filed: 2019-07-22
- Published: 2019-11-07
- Granted: 2021-01-26
- Earliest claimed: 2015-06-29
- Assignees: Ontogenesis, LLC
- Applicants: Ontogenesis, LLC
- Inventors: Gerald Horn
- Web page: https://patentgrep.com/patent/US10899712B2

## CPC

- C07D 215/22: attached in position 2 or 4
- C07C 233/57: having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C 233/60: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 2601/02: with a three-membered ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.

## Claims

### Claim 1

A compound of formula (V):
wherein X1 and X2 are each, individually a peptide, a protein or absent.

### Claim 2 (depends on 1)

A composition comprising a compound of claim 1 and one or more pharmaceutically acceptable excipients.